{"filing":{"accession_number":"0001720580-26-000049","cik":"0001720580","ticker":"ACET","company_name":"Adicet Bio, Inc.","form":"8-K","filing_date":"2026-08-05","report_date":"2026-08-05","primary_document":"acet-20260805.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1720580/000172058026000049/acet-20260805.htm"},"events":[{"id":25223,"run_id":22888,"accession_number":"0001720580-26-000049","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Adicet Bio announced its financial results for the quarter ended June 30, 2026, via press release furnished as Exhibit 99.1. The disclosure includes consolidated statements of operations showing Q2 2026 net loss of $21.4 million ($1.99 per share), R\u0026D and G\u0026A expenses, cash position of $118.2 million, and balance sheet information. This is a standard quarterly earnings release disclosure under Item 2.02, material to investors assessing the company's financial condition and cash runway.","company_name":"Adicet Bio, Inc.","ticker":"ACET","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":[{"id":25991,"accession_number":"0001720580-26-000049","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Adicet Bio announced its financial results for the quarter ended June 30, 2026, via press release furnished as Exhibit 99.1. The disclosure includes consolidated statements of operations showing Q2 2026 net loss of $21.4 million ($1.99 per share), R\u0026D and G\u0026A expenses, cash position of $118.2 million, and balance sheet information. This is a standard quarterly earnings release disclosure under Item 2.02, material to investors assessing the company's financial condition and cash runway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:20:31.269310+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":25991,"accession_number":"0001720580-26-000049","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Adicet Bio announced its financial results for the quarter ended June 30, 2026, via press release furnished as Exhibit 99.1. The disclosure includes consolidated statements of operations showing Q2 2026 net loss of $21.4 million ($1.99 per share), R\u0026D and G\u0026A expenses, cash position of $118.2 million, and balance sheet information. This is a standard quarterly earnings release disclosure under Item 2.02, material to investors assessing the company's financial condition and cash runway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:20:31.269310+00:00","company_name":"Adicet Bio, Inc.","ticker":"ACET","filing_date":"2026-08-05"}]}